Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pentaneuron-OD
- Development stage
- Unknown
- Lead developer
- Zinnia Life Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pentaneuron-OD is a neurotropic vitamin supplement developed and marketed by Zinnia Life Sciences. It is formulated as a combination of active ingredients including alpha-lipoic acid, benfotiamine, folic acid, inositol, mecobalamin, and pyridoxine. This combination is primarily used to support nerve health, rejuvenate damaged nerve cells, reduce oxidative stress, and manage symptoms associated with diabetic neuropathy and other peripheral neuropathies.
- Brand names
- Pentaneuron ODPentaneuron-OD
- Other names
- alpha-lipoic acid + benfotiamine + folic acid + inositol + mecobalamin + pyridoxine
Beyond the preview
Go deeper on Pentaneuron-OD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pentaneuron-OD.